Exploiting the mutanome for tumor vaccination - PubMed (original) (raw)
. 2012 Mar 1;72(5):1081-91.
doi: 10.1158/0008-5472.CAN-11-3722. Epub 2012 Jan 11.
Sebastian Kreiter, Jan Diekmann, Martin Löwer, Niels van de Roemer, Jos de Graaf, Abderraouf Selmi, Mustafa Diken, Sebastian Boegel, Claudia Paret, Michael Koslowski, Andreas N Kuhn, Cedrik M Britten, Christoph Huber, Ozlem Türeci, Ugur Sahin
Affiliations
- PMID: 22237626
- DOI: 10.1158/0008-5472.CAN-11-3722
Free article
Exploiting the mutanome for tumor vaccination
John C Castle et al. Cancer Res. 2012.
Free article
Abstract
Multiple genetic events and subsequent clonal evolution drive carcinogenesis, making disease elimination with single-targeted drugs difficult. The multiplicity of gene mutations derived from clonal heterogeneity therefore represents an ideal setting for multiepitope tumor vaccination. Here, we used next generation sequencing exome resequencing to identify 962 nonsynonymous somatic point mutations in B16F10 murine melanoma cells, with 563 of those mutations in expressed genes. Potential driver mutations occurred in classical tumor suppressor genes and genes involved in proto-oncogenic signaling pathways that control cell proliferation, adhesion, migration, and apoptosis. Aim1 and Trrap mutations known to be altered in human melanoma were included among those found. The immunogenicity and specificity of 50 validated mutations was determined by immunizing mice with long peptides encoding the mutated epitopes. One-third of these peptides were found to be immunogenic, with 60% in this group eliciting immune responses directed preferentially against the mutated sequence as compared with the wild-type sequence. In tumor transplant models, peptide immunization conferred in vivo tumor control in protective and therapeutic settings, thereby qualifying mutated epitopes that include single amino acid substitutions as effective vaccines. Together, our findings provide a comprehensive picture of the mutanome of B16F10 melanoma which is used widely in immunotherapy studies. In addition, they offer insight into the extent of the immunogenicity of nonsynonymous base substitution mutations. Lastly, they argue that the use of deep sequencing to systematically analyze immunogenicity mutations may pave the way for individualized immunotherapy of cancer patients.
Similar articles
- Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, Tadmor AD, Schoenberger SP, Huber C, Türeci Ö, Sahin U. Kreiter S, et al. Nature. 2015 Apr 30;520(7549):692-6. doi: 10.1038/nature14426. Epub 2015 Apr 22. Nature. 2015. PMID: 25901682 Free PMC article. - Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
Song S, Wang F, He X, He Y, Li D, Sun S. Song S, et al. Vaccine. 2007 Jun 15;25(25):4853-60. doi: 10.1016/j.vaccine.2006.12.029. Epub 2006 Dec 28. Vaccine. 2007. PMID: 17418455 - Characterization of mouse MAGE-derived H-2Kb-restricted CTL epitopes.
Eggert AO, Andersen MH, Voigt H, Schrama D, Kämpgen E, Straten PT, Becker JC. Eggert AO, et al. Eur J Immunol. 2004 Nov;34(11):3285-90. doi: 10.1002/eji.200324618. Eur J Immunol. 2004. PMID: 15384049 - Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA, Neelapu SS, Kwak LW, Biragyn A. Ruffini PA, et al. Haematologica. 2002 Sep;87(9):989-1001. Haematologica. 2002. PMID: 12217812 Review. - Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines.
Türeci Ö, Vormehr M, Diken M, Kreiter S, Huber C, Sahin U. Türeci Ö, et al. Clin Cancer Res. 2016 Apr 15;22(8):1885-96. doi: 10.1158/1078-0432.CCR-15-1509. Clin Cancer Res. 2016. PMID: 27084742 Review.
Cited by
- Tumor targeting peptide TMTP1 modified Antigen capture Nano-vaccine combined with chemotherapy and PD-L1 blockade effectively inhibits growth of ovarian cancer.
Zhou Y, Wei R, Wang L, Li J, Wang W, Jiang G, Tan S, Li F, Wang X, Ma X, Xi L. Zhou Y, et al. J Nanobiotechnology. 2024 Aug 13;22(1):483. doi: 10.1186/s12951-024-02744-6. J Nanobiotechnology. 2024. PMID: 39138475 Free PMC article. - Therapeutic Anti-Tumor Efficacy of DC-Based Vaccines Targeting TME-Associated Antigens Is Improved When Combined with a Chemokine-Modulating Regimen and/or Anti-PD-L1.
Taylor JL, Kokolus KM, Basse PH, Filderman JN, Cosgrove CE, Watkins SC, Gambotto A, Lowe DB, Edwards RP, Kalinski P, Storkus WJ. Taylor JL, et al. Vaccines (Basel). 2024 Jul 15;12(7):777. doi: 10.3390/vaccines12070777. Vaccines (Basel). 2024. PMID: 39066414 Free PMC article. - Neoantigen-specific T cell help outperforms non-specific help in multi-antigen DNA vaccination against cancer.
de Graaf JF, Pesic T, Spitzer FS, Oosterhuis K, Camps MGM, Zoutendijk I, Teunisse B, Zhu W, Arakelian T, Zondag GC, Arens R, van Bergen J, Ossendorp F. de Graaf JF, et al. Mol Ther Oncol. 2024 Jun 15;32(3):200835. doi: 10.1016/j.omton.2024.200835. eCollection 2024 Sep 19. Mol Ther Oncol. 2024. PMID: 39040850 Free PMC article. - Validation of novel conditional ligands and large-scale detection of antigen-specific T cells for H-2Dd and H-2Kd.
Sundebo Meldgaard T, Viborg N, Suarez Hernandez S, Vazquez Albacete D, Tamhane T, Reker Hadrup S. Sundebo Meldgaard T, et al. Sci Rep. 2024 May 29;14(1):12292. doi: 10.1038/s41598-024-62938-8. Sci Rep. 2024. PMID: 38811654 Free PMC article. - Glioma.
Weller M, Wen PY, Chang SM, Dirven L, Lim M, Monje M, Reifenberger G. Weller M, et al. Nat Rev Dis Primers. 2024 May 9;10(1):33. doi: 10.1038/s41572-024-00516-y. Nat Rev Dis Primers. 2024. PMID: 38724526 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous